Article

An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management.

Thyroid Board, Clinica Alemana de Santiago, Av. Vitacura 5951 Santiago, Chile.
The Journal of Clinical Endocrinology and Metabolism (Impact Factor: 6.31). 04/2009; 94(5):1748-51. DOI: 10.1210/jc.2008-1724
Source: PubMed

ABSTRACT There is a high prevalence of thyroid nodules on ultrasonographic (US) examination. However, most of them are benign. US criteria may help to decide cost-effective management.
Our objective was to develop a standardized US characterization and reporting data system of thyroid lesions for clinical management: the Thyroid Imaging Reporting and Data System (TIRADS).
This was a prospective study using the TIRADS, which is based on the concepts of the Breast Imaging Reporting Data System of the American College of Radiology.
A correlation of the US findings and fine needle aspiration biopsy (FNAB) results in 1959 lesions biopsied under US guidance and studied histologically during an 8-yr period was divided into three stages. In the first stage, 10 US patterns were defined. In the second stage, four TIRADS groups were defined according to risk. The percentages of malignancy defined in the Breast Imaging Reporting and Data System were followed: TIRADS 2 (0% malignancy), TIRADS 3 (<5% malignancy), TIRADS 4 (5-80% malignancy), and TIRADS 5 (>80% malignancy).
The TIRADS classification was evaluated at the third stage of the study in a sample of 1097 nodules (benign: 703; follicular lesions: 238; and carcinoma: 156). Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 88, 49, 49, 88, and 94%, respectively. The ratio of benign to malignant or follicular FNAB results currently is 1.8.
The TIRADS has allowed us to improve patient management and cost-effectiveness, avoiding unnecessary FNAB. In addition, we have established standard codes to be used both for radiologists and endocrinologists.

3 Bookmarks
 · 
344 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review was to assess the overall diagnostic accuracy of thyroid imaging reporting and data system (TI-RADS) classification in the differentiated diagnosis of patients with thyroid nodules. The diagnostic accuracy of TI-RADS was identified by using data from PubMed, the Cochrane Library, and other databases, which was from Jan 1966 to Dec 2013. Meta-analysis methods were used to obtain pooled sensitivity, specificity, negative likelihood ratio, positive likelihood ratio, diagnostic odds ratio, and summary receiver operating characteristic curves. A total of five studies with 7,753 thyroid nodules enrolled met the inclusion criteria in this meta-analysis. TI-RADS had a pooled sensitivity of 0.75 (95 % confidence interval 0.72-0.78) and a pooled specificity of 0.69 (95 % confidence interval 0.68-0.70). The pooled diagnostic odds ratio was 24.28 (95 % confidence interval 14.25-41.38). The overall area under the curve was 0.9177, and the Q* index was 0.8304. The TI-RADS classification was the accurate diagnostic technique for differentiating thyroid nodules.
    Tumor Biology 04/2014; · 2.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The indications of repeat fine-needle aspiration (FNA) for thyroid nodules with benign results of the Bethesda system were investigated. A total of 1,398 nodules were classified according to the Thyroid Imaging Reporting and Data System (TIRADS). TIRADS category 3 included nodules without solidity, hypoechogenicity or marked hypoechogenicity, microlobulated or irregular margins, microcalcifications, and taller-than-wide shape on ultrasonography (US). Categories 4a, 4b, 4c, and 5 included nodules with one, two, three or four, or five suspicious US features, respectively. The malignancy risks, and odds ratio (OR) with 95 % confidence interval (CI) were calculated. Analyses were performed for all nodules, nodules >10 mm, and nodules ≤10 mm. Of 1.398 nodules, 43 (3.1 %) were malignanct. The malignancy risks of benign nodules with categories 3, 4a, and 4b were 0.7, 1.2, and 0.7 %, respectively, whereas those for nodules with categories 4c and 5 were 9.8 and 22.2 %, respectively. The ORs of nodules with categories 4c and 5 were 19.4 (95 % CI 5.0-76.2) and 50.6 (95 % CI 10.4-245.0), respectively. In nodules >10 mm, the malignancy risks of categories 4c and 5 were 2.7 and 20 %, respectively, and the ORs were 10.7 (95 % CI 1.2-93.7) and 236.1 (95 % CI 12.6-4426.4), respectively. In nodules ≤ 10 mm, the malignancy risks of categories 4c and 5 were 12.6 and 22.6 %, respectively, and the ORs were 10.1 (95 % CI 1.3-78.0) and 18.9 (95 % CI 2.1-168.9), respectively. Repeat US-guided FNA should be considered in benign thyroid nodules with three or more suspicious US features regardless of size.
    Annals of Surgical Oncology 02/2014; · 4.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Thyroid cancer has been increasing in incidence, with the number of reported cases in the US rising by 25% over the last 3 years. With growing technological advances in the field and improved contributions of diagnostics, surgical decision-making and operative planning have taken on new challenges. Herein, we review the current clinical practice recommendations and active areas of surgical controversy, reflective of the most recently published professional consensus guidelines and a systematic review of the literature.
    Rambam Maimonides medical journal. 04/2014; 5(2):e0008.